LUPIN Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LUPIN, and what generic alternatives to LUPIN drugs are available?
LUPIN has two hundred and forty-four approved drugs.
There are nine US patents protecting LUPIN drugs. There are twenty-two tentative approvals on LUPIN drugs.
There are eighty-three patent family members on LUPIN drugs in twenty-four countries and seven hundred and thirty-two supplementary protection certificates in seventeen countries.
Summary for LUPIN
| International Patents: | 83 |
| US Patents: | 9 |
| Tradenames: | 199 |
| Ingredients: | 179 |
| NDAs: | 244 |
| Patent Litigation for LUPIN: | See patent lawsuits for LUPIN |
| PTAB Cases with LUPIN as petitioner: | See PTAB cases with LUPIN as petitioner |
Drugs and US Patents for LUPIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | VALSARTAN | valsartan | TABLET;ORAL | 201677-001 | Jan 5, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin | OSELTAMIVIR PHOSPHATE | oseltamivir phosphate | CAPSULE;ORAL | 208348-001 | Jan 9, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin Ltd | RUFINAMIDE | rufinamide | TABLET;ORAL | 204964-002 | Aug 17, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin | CHLORPROMAZINE HYDROCHLORIDE | chlorpromazine hydrochloride | TABLET;ORAL | 213327-002 | Jul 13, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin Ltd | PREGABALIN | pregabalin | CAPSULE;ORAL | 091040-007 | May 3, 2022 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LUPIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lupin | ANTARA (MICRONIZED) | fenofibrate | CAPSULE;ORAL | 021695-001 | Nov 30, 2004 | 7,863,331 | ⤷ Sign Up |
| Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 8,765,153 | ⤷ Sign Up |
| Lupin | BROVANA | arformoterol tartrate | SOLUTION;INHALATION | 021912-001 | Oct 6, 2006 | 7,541,385 | ⤷ Sign Up |
| Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 7,256,310 | ⤷ Sign Up |
| Lupin | XOPENEX HFA | levalbuterol tartrate | AEROSOL, METERED;INHALATION | 021730-001 | Mar 11, 2005 | 5,225,183 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LUPIN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Inhalation Solution | Eq. 0.015 mg base/2 mL | ➤ Subscribe | 2009-10-01 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | for Oral Suspension | 500 mg/5 mL | ➤ Subscribe | 2014-07-22 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 250 mcg/0.5 mL, 1 mL PFS | ➤ Subscribe | 2012-03-30 |
International Patents for LUPIN Drugs
Supplementary Protection Certificates for LUPIN Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0810209 | 33/2007 | Austria | ⤷ Sign Up | PRODUCT NAME: DARUNAVIR UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE; REGISTRATION NO/DATE: EU/1/06/380/001 - EU/1/06/380/008 20070212 |
| 0641330 | SPC/GB04/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PREGABALIN (S-(+)-4-AMINO-3(2-METHYLPROPYL)BUTANOIC ACID) OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACTIVE SALT.; REGISTERED: UK EU/1/04/279/001 20040706; UK EU/1/04/279/002 20040706; UK EU/1/04/279/003 20040706; UK EU/1/04/279/004 20040706; UK EU/1/04/279/005 20040706; UK EU/1/04/279/006 20040706; UK EU/1/04/279/025 20040706; UK EU/1/04/279/019 20040706; UK EU/1/04/279/020 20040706; UK EU/1/04/279/021 20040706; UK EU/1/04/279/022 20040706; UK EU/1/04/279/023 20040706; UK EU/1/04/279/024 20040706; UK EU/1/04/279/013 20040706; UK EU/1/04/279/014 20040706; UK EU/1/04/279/015 20040706; UK EU/1/04/279/016 20040706; UK EU/1/04/279/017 20040706; UK EU/1/04/279/018 20040706; UK EU/ |
| 1948158 | 2016C/026 | Belgium | ⤷ Sign Up | PRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUMZOUT COMPLEX, I.E. TRINATRIUM (3-((1S,3R)-1-BIFENYL-4-YLMETHYL-3-ETHOXYCARBONIL-1-BUTYLCARBAMOYL)PROPIONAAT-(S)-3'-METHYL-2'-(PENTANOYL(2-(TETRAZOL-5-YLATE)BIFENYL-4'-YLMETHYL)AMINO)BUTYRAAT)HEMIPENTAHYDRAAT; AUTHORISATION NUMBER AND DATE: EU/1/15/1058 20151123 |
| 1663240 | 2015/054 | Ireland | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 1261586 | 132012902044560 | Italy | ⤷ Sign Up | PRODUCT NAME: SAXAGLIPTIN E METFORMINA(KOMBOGLYZE); AUTHORISATION NUMBER(S) AND DATE(S): DA EU/1/11/731/001 A EU/1/11/731/014, 20111124 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
